This Patient Group Direction (PGD) must only be used by registered healthcare professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

PATIENT GROUP DIRECTION (PGD)

Supply and/or administration of ulipristal acetate 30mg tablet for emergency contraception

Within the Hampshire County Council and Isle of Wight Council Locally Commissioned Services for Emergency Hormonal Contraception

Version Number 1.0

Change History	
Version and Date	**Change details**
Version 1 October 2022	National templated use Supply and/or administration of ulipristal acetate 30mg tablet for emergency contraception: PGD template – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice (v1.1 Nov 2020)

This Patient Group Direction (PGD) must only be used by registered professionals who have been named and authorised by their organisation to practise under it (See Appendix A). The most recent and in date final signed version of the PGD must be used.

PGD DEVELOPMENT GROUP

Date PGD template comes into effect:	1st October 2022
Review date	30th September 2023
Expiry date:	31st March 2024

This PGD template has been peer reviewed by the Reproductive Health PGDs Short Life Working Group in accordance with their Terms of Reference. It has been approved by the Faculty for Sexual and Reproductive Health (FSRH) in November 2019.

This section MUST REMAIN when a PGD is adopted by an organisation.

Name	Designation
Dr Cindy Farmer	Chair General Training Committee Faculty of Sexual and Reproductive Healthcare (FSRH)
Michelle Jenkins	Advanced Nurse Practitioner, Clinical Standards Committee Faculty of Sexual and Reproductive Healthcare (FSRH)
Michael Nevill	Director of Nursing British Pregnancy Advisory Service (BPAS)
Katie Girling	British Pregnancy Advisory Service (BPAS)
Julia Hogan	CASH Nurse Consultant Marie Stopes UK
Kate Devonport	National Unplanned Pregnancy Association (NUPAS)
Chetna Parmar	Pharmacist adviser Umbrella
Helen Donovan	Royal College of Nursing (RCN)
Carmel Lloyd	Royal College of Midwives (RCM)
Clare Livingstone	Royal College of Midwives (RCM)
Leanne Bobb	English HIV and Sexual Health Commissioners Group (EHSHCG)
Deborah Redknapp	English HIV and Sexual Health Commissioners Group (EHSHCG)
Dipti Patel	Local authority pharmacist
Emma Anderson	Centre for Postgraduate Pharmacy Education (CPPE)
Dr Kathy French	Pan London PGD working group
Dr Sarah Pillai	Pan London PGD working group
Alison Crompton	Community pharmacist
Andrea Smith	Community pharmacist
Lisa Knight	Community Health Services pharmacist
Bola Sotubo	Clinical Commissioning Group pharmacist
Tracy Rogers	Associate Director Specialist Pharmacy Service
Sandra Wolper	Associate Director Specialist Pharmacy Service
Amanda Cooper	Specialist Pharmacy Service
Jo Jenkins (Woking Group Co-ordinator)	Specialist Pharmacist PGDs Specialist Pharmacy Service
Samrina Bhatti	Chief Pharmaceutical Officer's Clinical Fellow Specialist Pharmacy Service

ORGANISATIONAL AUTHORISATIONS

Name	Job title and organisation	Signature	Date
Dr Emma Harris **Senior doctor**	Clinical Director – Prescribing, South West Hampshire Place, Hampshire and Isle of Wight Integrated Care Board		26.9.22
Janna Whelan **Senior pharmacist**	Deputy Head of Medicines Optimisation, Hampshire and Isle of Wight Integrated Care Board		26.9.22
Neil Hardy **Senior representative of professional group using the PGD**	Associate Director – Medicines Optimisation, Hampshire and Isle of Wight Integrated Care Board		27.9.22
Simon Bryant **Person signing on behalf of authorising body**	Director of Public Health Hampshire County Council and Isle of Wight Council		28.9.22

1. Characteristics of staff

Qualifications and professional registration	Current contract of employment within the Local Authority or NHS commissioned service or the NHS Trust/organisation. Pharmacists to be registered with the General Pharmaceutical Council.
Initial training	The registered healthcare professional authorised to operate under this PGD must have undertaken appropriate education and training and successfully completed the competencies to undertake clinical assessment of patients ensuring safe provision of the medicines listed in accordance with local policy. Suggested requirement for training would be successful completion of a relevant contraception module/course accredited or endorsed by the FSRH, CPPE or a university. The healthcare professional has completed locally required training (including updates) in safeguarding children and vulnerable adults or level 2 safeguarding or the equivalent. Training should be successful completion of: CPPE open learning Emergency Hormonal Contraception CPPE open learning Contraception CPPE open learning Safeguarding children and vulnerable adults CPPE Emergency Contraception Declaration of Competence Additional local training as detailed in service specification and updates provided by L3 Sexual Health Service
Competency assessment	• Individuals operating under this PGD must be assessed as competent (see Appendix A) or complete a self-declaration of competence for emergency contraception. • Staff operating under this PGD are encouraged to review their competency using the NICE Competency Framework for health professionals using patient group directions
Ongoing training and competency	• Individuals operating under this PGD are personally responsible for ensuring that they remain up to date with the use of all medicines and guidance included in the PGD - if any training needs are identified these should be addressed and further training provided as required. • Organisational PGD and/or medication training as required by employing Trust/organisation.
The decision to supply any medication rests with the individual registered health professional who must abide by the PGD and any associated organisational policies.	

2. Clinical condition or situation to which this PGD applies

Clinical condition or situation to which this PGD applies	To reduce the risk of pregnancy after unprotected sexual intercourse (UPSI) or regular non-hormonal contraception has been compromised or used incorrectly.
Criteria for inclusion	• Any individual presenting for emergency contraception (EC) between 0 and 120 hours following UPSI or when regular non-hormonal contraception has been compromised or used incorrectly. • No contraindications to the medication. • Informed consent given.
Criteria for exclusion	• Informed consent not given. • Individuals under 16 years old and assessed as lacking capacity to consent using the Fraser Guidelines. • Individuals 16 years of age and over and assessed as lacking capacity to consent. • This episode of UPSI occurred more than 120 hours ago. N.B. A dose may be given if there have been previous untreated or treated episodes of UPSI within the current cycle if the most recent episode of UPSI is within 120 hours. • Known or suspected pregnancy (N.B. a previous episode of UPSI in this cycle is not an exclusion. Consider pregnancy test if more than three weeks after UPSI and no normal menstrual period). • Less than 21 days after childbirth. • Less than 5 days after miscarriage, abortion, ectopic pregnancy or uterine evacuation for gestational trophoblastic disease (GTD). • Known hypersensitivity to the active ingredient or to any component of the product - see Summary of Product Characteristics • Use of levonorgestrel or any other progestogen in the previous 7 days (i.e. hormonal contraception, hormone replacement therapy or use for other gynaecological indications). • Regular use of antacids, proton-pump inhibitors or H_2-receptor antagonists in the last 6 days. • Severe asthma controlled by oral glucocorticoids. • Individuals using enzyme-inducing drugs/herbal products or within 4 weeks of stopping. • Acute porphyria
Cautions including any relevant action to be taken	• All individuals should be informed that insertion of a copper intrauterine device (Cu-IUD) within five days of UPSI or within five days from earliest estimated ovulation is the most effective method of emergency contraception. **If a Cu-IUD is appropriate and acceptable supply oral EC and refer to the appropriate health service**

	provider. Patient to call Level 3 Sexual Health Service on 0300 300 2016 as soon as possible and request an emergency contraception IUD. • Ulipristal is ineffective if taken after ovulation. • If individual vomits within three hours from ingestion, a repeat dose may be given. • Body Mass Index (BMI) >26kg/m2 or weight >70kg – individuals should be advised that though oral EC methods may be safely used, a high BMI may reduce the effectiveness. A Cu-IUD should be recommended as the most effective method of EC. • Consideration should be given to the current disease status of those with severe malabsorption syndromes, such as acute/active inflammatory bowel disease or Crohn's disease. Although the use of ulipristal is not contra-indicated it may be less effective and so these individuals should be advised that insertion of Cu-IUD would be the most effective emergency contraception for them and referred accordingly if agreed. • Breast feeding – advise to express and discard breast milk for 7 days after ulipristal dose. • The effectiveness of ulipristal can be reduced by progestogen taken in the following 5 days and individuals must be advised not to take progestogen containing drugs for 5 days after ulipristal. See section 'Written information and further advice to be given to individual'. • All individuals under 18 years of age should have a child sexual exploitation risk assessment (CSERQ4). • If the individual is less than 16 years of age an assessment based on Fraser guidelines must be made and documented. • If the individual is less than 13 years of age the healthcare professional should speak to local safeguarding lead and follow the local safeguarding policy. See Safeguarding Children Partnership Procedures, contact the professionals line and complete Interagency Referral Form (IARF) where possible. • **All immediate safeguarding concerns should be made initially by telephone to the Children's Services Professionals line 01329 225379 or by email to csprofessional@hants.gov.uk Professionals on the Isle of Wight should call 0300 300 0901 or email iowcsprofessional@hants.gov.uk Calls to the Children's Services Professionals' line number will be automatically redirected to the Out of Hours Service outside normal office hours.** • If the individual has not yet reached menarche consider onward referral for further assessment or investigation.

Action to be taken if the individual is excluded or declines treatment	• Explain the reasons for exclusion to the individual and document in the consultation record. • Record reason for decline in the consultation record. • Offer suitable alternative emergency contraception or refer the individual as soon as possible to a suitable health service provider if appropriate and/or provide them with information about further options, including: ○ Level 3 Sexual Health Service (including for Cu-IUD for emergency contraception: 0300 300 2016 or www.letstalkaboutit.nhs.uk)

3. Description of treatment

Name, strength & formulation of drug	Ulipristal acetate 30mg tablet
Legal category	P
Route of administration	Oral
Off label use	Best practice advice given by Faculty of Sexual and Reproductive Healthcare (FSRH) is used for guidance in this PGD and may vary from the Summary of Product Characteristics (SPC). This PGD includes off-label use in the following conditions: • Lapp-lactase deficiency • Hereditary problems of galactose intolerance • Glucose-galactose malabsorption • Severe hepatic impairment Drugs should be stored according to the conditions detailed in the Storage section in this table. However, in the event of an inadvertent or unavoidable deviation of these conditions the local pharmacy or Medicines Optimisation team must be consulted. Where drugs have been assessed by pharmacy/Medicines Optimisation team in accordance with national or specific product recommendations as appropriate for continued use this would constitute off-label administration under this PGD. The responsibility for the decision to release the affected drugs for use lies with the pharmacy and the Medicines Optimisation team. Where a drug is recommended off-label consider, as part of the consent process, informing the individual/parent/carer that the drug is being offered in accordance with national guidance but that this is outside the product licence.
Dose and frequency of administration	• One tablet (30mg) as a single dose taken as soon as possible up to 120 hours after UPSI.

Duration of treatment	• A single dose is permitted under this PGD.
	• If vomiting occurs within 3 hours of ulipristal being taken a repeat dose can be supplied under this PGD.
	• Repeated doses can be given within the same cycle. Please note:
	  ○ If within 7 days of previous levonorgestrel offer levonorgestrel again (not ulipristal)
	  ○ If within 5 days of ulipristal then offer ulipristal again (not levonorgestrel)

Quantity to be supplied	Appropriately labelled pack of one tablet.
Storage	Medicines must be stored securely according to national guidelines and in accordance with the product SPC.

Drug interactions	A detailed list of drug interactions is available in the SPC, which is available from the electronic Medicines Compendium website: www.medicines.org.uk or the BNF www.bnf.org
Identification & management of adverse reactions	A detailed list of adverse reactions is available in the SPC, which is available from the electronic Medicines Compendium website: www.medicines.org.uk and BNF www.bnf.org The following side effects are common with ulipristal acetate (but may not reflect all reported side effects): • Nausea or vomiting • Abdominal pain or discomfort • Headache • Dizziness • Muscle pain (myalgia) • Dysmenorrhea • Pelvic pain • Breast tenderness • Mood changes • Fatigue • The FSRH advises that disruption to the menstrual cycle is possible following emergency contraception.
Management of and reporting procedure for adverse reactions	• Healthcare professionals and patients/carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on: http://yellowcard.mhra.gov.uk • Record all adverse drug reactions (ADRs) in the patient's medical record. • Report any adverse reactions via organisation incident policy.
Written information and further advice to be given to individual	• All methods of emergency contraception should be discussed. All individuals should be informed that fitting a Cu-IUD within five days of UPSI or within five days from the earliest estimated ovulation is the most effective method of emergency contraception. The individual requesting emergency contraception should be provided with EHC if clinically appropriate and advised to call the Level 3 Sexual Health Service on 0300 300 2016 and ask for emergency contraception IUD (www.letstalkaboutit.nhs.uk) • Ensure that a patient information leaflet (PIL) is provided within the original pack. • If vomiting occurs within three hours of taking the dose, the individual should return for another dose. If this could be outside of opening hours, ensure woman knows of other local pharmacy that will be open and provides service such as 100hr pharmacy. • Explain that menstrual disturbances can occur after the use of emergency hormonal contraception.

	• Provide advice on ongoing contraceptive methods, including how these can be accessed. Further information available at www.letstalkaboutit.nhs.uk.
	• Repeated episodes of UPSI within one menstrual cycle - the dose may be repeated more than once in the same menstrual cycle should the need occur.
	• In line with FSRH guidance individuals using hormonal contraception should delay restarting their regular hormonal contraception for 5 days following ulipristal acetate use. Avoidance of pregnancy risk (i.e. use of condoms or abstain from intercourse) should be advised until fully effective.
	• Advise a pregnancy test three weeks after treatment especially if the expected period is delayed by more than seven days or abnormal (e.g. shorter or lighter than usual), or if using hormonal contraception which may affect bleeding pattern.
	• Promote the use of condoms to protect against sexually transmitted infections (STIs) and advise on the possible need for screening for STIs. More information at www.letstalkaboutit.nhs.uk, including:
	  ○ Free condom by post service
	  ○ Free STI tests, including testing by post.
	• Free condom pack to be provided to all under 25-year-old individuals if pharmacy participates in scheme. If not signpost to website for supply.
	• Signpost all under 25-year-old individuals to free Chlamydia online test kit
	• There is no evidence of harm if someone becomes pregnant in a cycle when they had used emergency hormonal contraception.

Advice / follow up treatment	• The individual should be advised to seek medical advice in the event of an adverse reaction.
	• The individual should attend an appropriate health service provider if their period is delayed, absent or abnormal or if they are otherwise concerned.
	• Pregnancy test as required (see advice to individual above).
	• Individuals advised how to access on-going contraception and STI screening as required:
	  ○ Ongoing contraception via GP or Level 3 Sexual Health Service www.letstalkaboutit.nhs.uk or call 0300 300 2016
	  ○ STI screening visit www.letstalkaboutit.nhs.uk or call 0300 300 2016

Records	Record: • The consent of the individual and ○ If individual is under 13 years of age record action taken

	○ If individual is under 16 years of age document capacity using Fraser guidelines. If not competent record action taken. ○ If individual over 16 years of age and not competent, record action taken ○ If individual is under 18 years of age, document CSE risk assessment questionnaire • Name of individual, address, date of birth • GP contact details where appropriate • Relevant past and present medical history, including medication history. Examination finding where relevant e.g. weight • Any known medication allergies • Name of registered health professional operating under the PGD • Name of medication supplied • Date of supply • Dose supplied • Quantity supplied • Advice given, including advice given if excluded or declines treatment • Details of any adverse drug reactions and actions taken • Advice given about the medication including side effects, benefits, and when and what to do if any concerns • Any referral arrangements made • Any supply outside the terms of the product marketing authorisation • Recorded that administered/supplied via Patient Group Direction (PGD) Records should be signed and dated (or a password controlled e-records) and securely kept for a defined period in line with local policy. All records should be clear, legible and contemporaneous. A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy.

4. Key references

Key references (accessed December 2019)	• Electronic Medicines Compendium http://www.medicines.org.uk/ • Electronic BNF https://bnf.nice.org.uk/ • NICE Medicines practice guideline "Patient Group Directions" https://www.nice.org.uk/guidance/mpg2 • Faculty of Sexual and Reproductive Health Clinical Guidance: Emergency Contraception - December 2017 https://www.fsrh.org/standards-and-guidance/current-clinical-

	guidance/emergency-contraception/ • Faculty of Sexual and Reproductive Health Drug Interactions with Hormonal Contraception - November 2017 https://www.fsrh.org/standards-and-guidance/current-clinical-guidance/drug-interactions/ • Royal Pharmaceutical Society Safe and Secure Handling of Medicines December 2018 https://www.rpharms.com/recognition/setting-professional-standards/safe-and-secure-handling-of-medicines

Appendix A - Registered health professional authorisation sheet

Patient Group Direction (PGD) for the supply and/or administration of ulipristal acetate 30mg tablet for emergency contraception

Within the Hampshire and Isle of Wight Locally Commissioned Services for Emergency Hormonal Contraception

PGD Name/Version: HCCIWC_Upa_2022v1 Valid from:1.10.2022 Expiry:31.03.2024

Before signing this PGD, check that the document has had the necessary authorisations. Without these, this PGD is not lawfully valid.

Registered health professional

By signing this patient group direction you are indicating that you agree to its contents and that you will work within it.

Patient group directions do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

Pharmacy Name and Address where PGD to be used: **Name:** **Address:** **Post Code:**			
Pharmacy F Code:			
I confirm that I have read and understood the content of this Patient Group Direction and that I am willing and competent to work to it within my professional code of conduct.			
Name	**Designation**	**Signature**	**Date**

Authorising manager

I confirm that the registered health professionals named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf …… (insert name of organisation) for the above-named health care professionals who have signed the PGD to work under it.			
Name	**Designation**	**Signature**	**Date**

Note to authorising manager

Score through unused rows in the list of registered health professionals to prevent additions post managerial authorisation. This authorisation sheet should be retained by the Pharmacy to serve as a record of those registered health professionals authorised to work under this PGD.

Authorisation to work under the Locally Commissioned Service PGD is provided electronically by the Authorising Organisation via the Declaration of Competence via the E-Recording System used to monitor emergency contraception provision.

The PGD document and authorisation sheet should be retained to serve as a record of those registered health professionals authorised to work under this PGD.